What evidence supports the use of immunotherapy in early-stage (stage I–II) nasopharyngeal carcinoma?

Immunotherapy is NOT currently recommended for early-stage (stage I-II) nasopharyngeal carcinoma based on existing guidelines and evidence.

Current Standard of Care for Early-Stage NPC

For stage I-II nasopharyngeal carcinoma, radiotherapy alone remains the standard treatment, with no role for immunotherapy in this setting 1, 2. The most recent ESMO-EURACAN guidelines (2023) explicitly state that stage I-II disease should be treated with RT alone, and when IMRT is used, this approach applies to stage II disease as well 1.

Where Immunotherapy IS Supported

The evidence for immunotherapy in NPC is robust, but specifically for different disease stages:

Locoregionally Advanced Disease (Stage III-IVA)

• Recent trials have explored immunotherapy integration in high-risk locoregionally advanced NPC
• The 2023 ESMO guidelines focus on adjuvant capecitabine (not immunotherapy) for this population 1
• Emerging research suggests potential benefit when ICIs are added to multimodality therapy, with pooled 3-year OS of 96.4% and FFS of 88.2% 3
• However, these remain investigational approaches not yet incorporated into standard guidelines for curative-intent treatment

Recurrent/Metastatic Disease

This is where immunotherapy has the strongest evidence and guideline support:

• Two randomized phase III trials demonstrated improved PFS when camrelizumab or toripalimab was added to first-line cisplatin-gemcitabine chemotherapy 1
• The addition of immunotherapy should be considered for recurrent/metastatic NPC 1
• As monotherapy, nivolumab, pembrolizumab, and camrelizumab showed ORRs of 20%, 25%, and 34% respectively in this setting 2

Key Clinical Reasoning

The biological rationale for immunotherapy in NPC is compelling—the causal role of EBV creates opportunities for immune-mediated responses 2. However, early-stage disease has excellent outcomes with RT alone, making it difficult to demonstrate additional benefit from immunotherapy while potentially adding toxicity and cost.

Common Pitfalls to Avoid

• Do not extrapolate the recurrent/metastatic data to early-stage disease
• Do not confuse locoregionally advanced (stage III-IVA) with early-stage (I-II) disease—these are fundamentally different treatment paradigms
• The emerging research on ICI integration in locoregionally advanced disease 4, 5, 3 does not apply to stage I-II patients

Treatment Algorithm for Stage I-II NPC

1. Stage I: Intensity-modulated radiotherapy (IMRT) alone to 70 Gy for gross disease 2
2. Stage II: IMRT alone when using modern techniques 2
3. No chemotherapy is indicated for these early stages
4. No immunotherapy has demonstrated benefit or guideline support

If considering clinical trial enrollment, this would be the only appropriate context for immunotherapy use in early-stage NPC, as the standard evidence base does not support its routine integration 1, 2.